Austar Lifesciences Limited provided unaudited consolidated earnings guidance for the year ended 31 December 2019. For the year, the Group is expected to record a profit attributable to the owners of the Company of no less than approximately RMB 8 million for the year ended 31 December 2019, as compared to the profit attributable to the owners of the Company of approximately RMB 0.1 million for the year ended 31 December 2018. The Board attributes the expected increase in profit principally to the significant growth of revenue and gross profit, which is mainly attributable to the higher level of backlog as at 31 December 2018 and a substantial increase in the amount of order-in-take of the Group for the year ended 31 December 2019, resulting in a higher amount of revenue and profit being recognised for the year ended 31 December 2019.